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Background: Left ventricular hypertrophy (LVH) is prevalent in patients with type 2 diabetes mellitus (T2DM).
Recent studies show that an increase in albumin-adjusted serum calcium level is associated with an elevated risk of
T2DM. We speculate that increased serum calcium levels in T2DM patients are related to LVH prevalence.
Methods: In this echocardiographic study, 833 normocalcemia and normophosphatemia patients with T2DM were
enrolled. The associations between serum calcium and metabolic parameters, left ventricular mass index (LVMI), as
well as the rate of LVH were examined using bivariate linear correlation, multivariate linear regression and logistic
regression, respectively. The predictive performance of serum calcium for LVH was evaluated using the area under
the receiver operating characteristic curve (AUC).
Results: Patients with LVH have significantly higher serum calcium than those without LVH. Serum calcium was
positively associated with total cholesterol, triglycerides, low-density lipoprotein cholesterol, serum uric acid, HOMA-IR
and fasting plasma glucose. Multivariate linear regression analysis demonstrated that serum calcium was independently
associated with LVMI (p < 0.001). In comparison with patients in the lowest serum calcium quartile, the odds ratio (OR)
for LVH in patients in the highest quartile was 2.909 (95% CI 1.792-4.720; p < 0.001). When serum calcium was analyzed
as a continuous variable, per 1 mg/dl increase, the OR (95% CI) for LVH was [2.400 (1.552-3.713); p < 0.001]. Serum
calcium can predict LVH (AUC = 0.617; 95% CI (0.577-0.656); p < 0.001).
Conclusions: Albumin-adjusted serum calcium is associated with an increased risk of LVH in patients with T2DM.
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Left ventricular hypertrophy (LVH) is a threatening prog-
nostic sign and an independent risk factor for cardiac
death, coronary heart disease, ventricular dysrhythmias,
and heart failure [1]. The presence of type 2 diabetes mel-
litus (T2DM) per se is independently associated with
LVH, even in the absence of hypertension and obesity
[2-4]. Several mechanisms such as insulin resistance,
hyperlipidemia and diabetic kidney damage have been
proposed to explain the relationship between T2DM and
LVH. But after adjusting those potentially risk factors* Correspondence: renminghu@hotmail.com
†Equal contributors
1The Institute of Endocrinology and Diabetology, Huashan Hospital, Shanghai
Medical College, Fudan University, 12 Middle Wulumuqi Road, Shanghai
200040, China
Full list of author information is available at the end of the article
© 2015 Li et al.; licensee BioMed Central. This
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.including glycaemia control, blood lipids, urinary albu-
min excretion rate and homeostasis model assessment
insulin resistance (HOMA-IR), LVH is still a common
condition in patients with T2DM [5,6]. Consequently,
screening additional possible risk factors in the devel-
opment of LVH in diabetic patients is an important
subject of investigation.
Cumulative evidences reveal that an alteration in cal-
cium homeostasis (indexed by serum calcium level) ac-
companies the diabetic state [7-10]. Serum calcium level
is positively correlated with blood lipids and glucose
levels in T2DM after adjustment for parathyroid hormone
(PTH) as well as age, body weight, height, creatinine, albu-
min, or bone metabolism [8-10]. Moreover, an increase in
serum calcium level is associated with an increased risk ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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secretion and insulin resistance [12].
Based on these findings, we speculate that an alteration
in calcium homeostasis is associated with LVH prevalence,
and we conduct a cross-sectional study to evaluate rela-




A total of 833 subjects (486 men and 347 women) were
included in this study. We recruited consecutive subjects
who visited Huashan Hospital for education, evaluation,
or treatment of T2DM from 2010 to 2014. To minimize
the possibility that some abnormal conditions may influ-
ence the results, patients with any of the following con-
ditions were excluded: 1) serum creatinine > 130 μmol/L
(normal range: 50–130 μmol/L) or urine albumin per
gram urine creatinine (Alb/Cr) > 300 mg/g; 2) a history
of parathyroid disease or vitamin D-related disorders, as
well as other diseases which can affect vitamin D ab-
sorption and metabolism; 3) medication history includ-
ing vitamin D, bisphosphonate, estrogen replacement
therapy and diuretics which may influence calcium me-
tabolism within the past 1 month; 4) serum calcium out
of normal range from central laboratory of Huashan
hospital (8.42-10.42 mg/dl, or 2.10-2.60 mmol/l); 5) serum
phosphate out of normal range from central laboratory of
Huashan hospital (3.00-4.50 mg/dl, or 0.97-1.45 mmol/l);
6) a history of myocardial infarction, coronary artery by-
pass or angioplasty, atrial fibrillation, moderate and severe
valvular heart disease, stroke or occlusive peripheral vas-
cular disease, heart failure; 7) uncontrolled thyroid dis-
eases, or active urinary tract infection. This study was
approved by the ethical review board of Huashan Hospital
and complied with the Helsinki declaration. Written in-
formed consent was obtained from all participants.
Biochemical measurements
A 12-hour overnight fasting venous blood sample was
collected in all subjects. A morning fasting spot urine
sample was collected once every month for three consecu-
tive months to estimate the urinary albumin-to-urinary
creatinine ratio. The creatinine, albumin, calcium, phos-
phate, uric acid, total cholesterol (TC), triglycerides (TG),
low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), and fasting plasma
glucose (FPG) were measured by biochemical auto analyzer
(Abbott C8000). The fasting insulin concentration was
measured by electrochemiluminescence immunoassay
technique (Roche Elecsys 2010). HbA1c was measured by
high performance liquid chromatography (HPLC; Bio-Rad,
Hercules, CA, USA). Serum calcium level was corrected
according to the formula: albumin-adjusted serum calciumconcentration (mg/dl) = measured serum calcium con-
centration (mg/dl) + 0.8 × [4 − serum albumin concen-
tration (g/dl)] [11]. Insulin resistance was determined
using the homeostatic model assessment: HOMA-IR =
fasting plasma glucose (mmol/l) × fasting plasma insulin
(mIU/L)/22.5 [13].
Echocardiography
As recommended by the American Society of Echocardi-
ography [14], with patients in partial left lateral decubitus
positions, echocardiographic examination was performed
under two-dimensional guided M-mode with a Vingmed
System 5 Doppler echocardiographic unit (GE Vingmed
Ultrasound, Horten, Norway). Left ventricular mass (LVM)
was calculated by the Devereux formula [15]: LVM (g) =
0.8{1.04 [([LVIDD (left ventricular internal diameter,
diastolic) + PWTD (posterior wall thickness, diastolic) +
IVSD (inter ventricular septum, diastolic)]3 − LVIDD3)]} +
0.6. Relative wall thickness (RWT) was calculated as 2 ×
PWTD /LVIDD and increased RWT was defined as > 0.42
[16]. LVM index (LVMI) was derived by correcting
LVM for body surface area [BSA (m2) = 0.007184 ×Height
(cm)0.725 ×Weight (kg)0.425] [17]. LVH was defined as fol-
lows: LVMI > 115 g/m2 for men and LVMI > 95 g/m2 for
women [16]. LV geometry was defined as “normal” (both
RWT and LVMI normal), “concentric remodeling” (in-
creased RWT but normal LVMI), “eccentric hypertrophy”
(increased LVMI but normal RWT), and “concentric
hypertrophy” (both LVMI and RWT increased) [16].
Others
T2DM was defined as the onset of diabetes after the age
of 35. Diabetes was diagnosed by the American Diabetes
Association guideline [18]. Body mass index (BMI, kg/m2)
was defined as weight divided by square height. Obesity
was defined as BMI ≥ 28 kg/m2 according to Chinese stand-
ard [19]. Smoking was defined as “ever smoked” as com-
pared to “never smoked”. Hypertension was defined as
systolic blood pressure (SBP) ≥ 140 mmHg and/or dia-
stolic blood pressure (DBP) ≥90 mmHg, or current antihy-
pertensive therapy. Micro-albuminuria was defined as
Alb/Cr between 30 and 300 mg/g, and macro-albuminuria
was defined as Alb/Cr > 300 mg/g. Dyslipidemia was de-
fined as HDL-C < 1.04 mmol/l, LDL-C ≥ 4.14 mmol/l, or
TG ≥ 2.26 mmol/l [20].
Data analysis
Descriptive statistics of mean and standard deviation
(SD) were calculated for continuous variables, as well
as frequencies and percentages for categorical variables.
Kolmogorov-Smirnov Test was used to judge whether
continuous variable followed normal distribution. HOMA-IR
and Alb/Cr were logarithmically transformed to approxi-
mate normal distribution before analysis. Differences in
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samples T-test or One-way ANOVA. If data were non-
normal distributed or not met the homogeneity of variances,
nonparametric test was used. Chi-square test was used
for categorical variables. The associations between serum
calcium and metabolic parameters were examined using
bivariate linear correlation (Pearson correlation). Using
factors identified by the initial univariate linear regression,
a stepwise multiple linear regression was carried out to
determine independent variable’s contribution to LVMI.
Collinearity diagnostics was used to confirm whether the
predictors are highly intercorrelated. Logistic regression
analysis was performed using LVH as the dependent vari-
able to analyze the association between albumin-adjusted
serum calcium level and LVH after adjusting for additional
variables such as Alb/Cr, creatinine, albumin, SBP, age,
gender, smoking, the use of ACEI/ARB medication, dyslip-
idemia, HbA1c, obesity and HOMA-IR. Odds ratios (OR)
with 95% confidence intervals (CI) were calculated for the
relative risk of elevated albumin-adjusted serum calcium
level with LVH. The abilities to predict LVH of albumin-
adjusted serum calcium, Alb/Cr and SBP were evaluated
using the area under the curve (AUC) in the receiver op-
erating characteristic (ROC) curve. Data were processed
using Statistical Product and Service Solutions (SPSS) ver-




The subjects in this study were 486 men and 347 women
with T2DM (mean ages, 68.2 ± 13.9 and 67.0 ± 10.5, re-
spectively; Table 1). The duration of diabetes was 10.4 ±
8.5 years. Hypertension, micro-albuminuria, dyslipidemia
and obesity were present in 429 (51.5%), 476 (57.1%),
448 (53.8%) and 124 (14.9%) patients, respectively.
Significant difference in albumin-adjusted serum calcium
was observed between non-LVH and LVH group (8.93 ±
0.35 vs. 9.09 ± 0.40 mg/dl, p < 0.001, Table 1). Percentage of
the subjects with hypertension, micro-albuminuria, dyslip-
idemia, obesity and the use of ACEI/ARB were higher in
subjects with LVH (eccentric or concentric hypertrophy)
than those without LVH (normal or concentric remod-
eling). The patients with LVH also had higher levels of
SBP, DBP, Alb/Cr, TG, and serum calcium-phosphate
product, longer duration of diabetes, and lower levels of
serum albumin.
Compared to subjects in albumin-adjusted serum cal-
cium quartile 1 (8.42 – 8.69 mg/dl), those in quartile 4
(9.23 – 10.42 mg/dl) had significant higher percentage of
LVH (53.5% vs. 23.0%, p < 0.001, Table 2). FPG, HOMA-
IR, albumin, Alb/Cr, TC, LDL-C, phosphate, percentage
of the subjects with LVH and micro-albuminuria, and
duration of diabetes differed across albumin-adjustedserum calcium quartiles. From quartile 1 to quartile 4, per-
centage of the subjects with LVH and micro-albuminuria,
levels of Alb/Cr, TC, LDL-C, FPG, HOMA-IR and phos-
phate have significant overall upward tendencies; more-
over, levels of serum uric acid, creatinine and TG, and
percentage of the subjects with dyslipidemia also have
overall upward tendencies but non-significant.
Serum calcium and metabolism-related parameters
Table 3 showed that albumin-adjusted serum calcium level
was significantly and positively correlated with metabolism-
related parameters such as FPG (r = 0.207, p < 0.001),
HOMA-IR (r = 0.137, p < 0.001), uric acid (r = 0.165, p <
0.001), TG (r = 0.100, p = 0.004), TC (r = 0.119, p = 0.001)
and LDL-C (r = 0.094, p = 0.007).
LVMI and LVH
As we know, greater LVMI (a widely used method to as-
sess LVH) corresponded to higher severity of LVH. From
albumin-adjusted serum calcium quartile 1 to quartile 4,
LVMI significantly (p < 0.001) increased from 94.20 ±
19.02 g/m2 to 111.21 ± 27.93 g/m2 (Table 2).
After the initial univariate linear regression analysis to
select variables from factors including albumin-adjusted
serum calcium, uric acid, the use of ACEI or ARB medica-
tion, age, gender, smoking, HbA1c, obesity, HOMA-IR,
phosphate, creatinine, albumin, Alb/Cr, SBP, DBP, and dys-
lipidemia, the stepwise multiple linear regression (Table 4)
showed that higher LVMI was associated with albumin-
adjusted serum calcium, Alb/Cr, creatinine, obesity, serum
albumin and dyslipidemia. There was no obvious collin-
earity among these predictors. Albumin-adjusted serum
calcium was an independent factor that could influence
LVMI, with a standardized regression coefficient at 0.193
(p < 0.001).
The logistic regression analysis (Table 5) shows the
ORs (95% CI) for LVH according to changes in albumin-
adjusted serum calcium levels when calcium is a categor-
ical variable (quartiles) or a continuous variable (1 mg/dl).
In contrast to subjects in quartile 1 (8.42-8.69 mg/dl),
there were significantly increased risk of LVH with sub-
jects in quartile 2 [(8.70-8.93 mg/dl), OR (95% CI) = 1.836
(1.152-2.924), p = 0.011] and quartile 4 [(9.23-10.42 mg/dl),
OR (95% CI) = 2.909 (1.792-4.720), p < 0.001], after adjusted
for possible confounding factors including Alb/Cr, creatin-
ine, albumin and SBP in model 1, further adjusted for age,
gender and smoking and the use of ACEI or ARB medica-
tion in model 2, and furthermore adjusted for dyslipid-
emia, HbA1c, obesity and HOMA-IR in model 3. Subjects
in quartile 3 (8.94-9.22 mg/dl) also had a tendency (OR =
1.624) to develop LVH compared to those in quartile 1,
but the P value was non-significant (p = 0.054). When cal-
cium was analyzed as a continuous variable, in model 3,
for every 1 mg/dl increase in the albumin-adjusted serum
Table 1 Baseline characteristics of subjects categorized by LVH and LV geometry
Characteristics LVH LV geometry







Age (year) 67.8 ± 13.6 67.6 ± 10.8 0.823 67.6 ± 13.4 68.3 ± 14.0 66.5 ± 10.4 68.5 ± 11.0 0.188
Male, n (%) 371 (71.3) 115 (36.7) <0.001 243 (71.7) 128 (70.7) 47 (33.6) 68 (39.3) <0.001
Hypertension, n (%) 237 (45.6) 192 (61.3) <0.001 151 (44.5) 86 (47.5) 79 (56.4) 113 (65.3) <0.001
ACEI/ARB use, n (%) 219 (42.1) 159 (50.8) 0.015 139 (41.0) 80 (44.2) 59 (42.1) 100 (57.8) 0.003
Smoking, n (%) 116 (22.3) 74 (23.6) 0.657 72 (21.2) 44 (24.3) 36 (25.7) 38 (22.0) 0.695
Duration of diabetes (year) 9.8 ± 8.1 11.4 ± 9.0 0.010 9.4 ± 7.8 10.6 ± 8.7 11.5 ± 9.4 11.3 ± 8.7 0.023
SBP (mmHg) 134.7 ± 19.5 140.7 ± 19.3 <0.001 134.3 ± 19.4 135.4 ± 19.6 141.4 ± 21.4 140.2 ± 17.5 <0.001
DBP (mmHg) 78.7 ± 10.9 80.3 ± 11.2 0.048 79.2 ± 10.4 77.7 ± 11.7 78.6 ± 11.2 81.6 ± 11.0 0.008
BMI (Kg/M2) 24.2 ± 3.3 24.7 ± 4.5 0.079 24.0 ± 3.0 24.4 ± 3.8 25.2 ± 4.1 24.3 ± 4.8 0.038
Obesity, n (%) 56 (10.8) 68 (21.7) <0.001 33 (9.7) 23 (12.7) 38 (27.1) 30 (17.3) <0.001
Laboratory
FPG (mmol/L) 7.85 ± 3.11 7.78 ± 3.21 0.785 7.97 ± 3.31 7.63 ± 2.67 7.37 ± 2.43 8.12 ± 3.70 0.369
lg HOMA-IR 0.56 ± 0.32 0.61 ± 0.34 0.069 0.56 ± 0.33 0.57 ± 0.30 0.58 ± 0.31 0.62 ± 0.36 0.166
HbA1c (%) 8.16 ± 1.89 8.08 ± 1.98 0.518 8.17 ± 1.95 8.16 ± 1.78 8.03 ± 1.97 8.12 ± 2.00 0.898
Albumin (g/L) 39.19 ± 4.70 37.66 ± 5.24 <0.001 39.31 ± 4.62 38.96 ± 4.86 37.14 ± 5.46 38.08 ± 5.03 <0.001
Uric acid (μmol/L) 335.63 ± 100.71 342.15 ± 104.57 0.373 332.59 ± 101.36 341.31 ± 99.52 345.48 ± 110.94 339.45 ± 99.37 0.589
Creatinine (μmol/L) 81.23 ± 22.28 84.10 ± 27.90 0.123 80.42 ± 21.41 82.77 ± 23.80 86.91 ± 30.03 81.82 ± 25.91 0.531
lg Alb/Cr (mg/g) 1.57 ± 0.70 1.94 ± 0.63 <0.001 1.49 ± 0.68 1.72 ± 0.73 1.99 ± 0.62 1.90 ± 0.63 <0.001
Micro-albuminuria, n (%) 246 (47.3) 230 (73.5) < 0.001 147 (43.4) 99 (54.7) 103 (73.6) 127 (73.4) < 0.001
TG (mmol/L) 1.76 ± 1.11 1.95 ± 1.30 0.026 1.79 ± 1.21 1.71 ± 0.89 1.90 ± 1.43 1.99 ± 1.18 0.113
TC (mmol/L) 4.75 ± 1.18 4.91 ± 1.13 0.065 4.69 ± 1.19 4.87 ± 1.15 4.96 ± 1.15 4.87 ± 1.12 0.093
HDL-C (mmol/L) 1.11 ± 0.30 1.11 ± 0.46 0.781 1.11 ± 0.29 1.12 ± 0.31 1.14 ± 0.59 1.08 ± 0.32 0.301
LDL-C (mmol/L) 2.70 ± 0.86 2.77 ± 0.83 0.221 2.67 ± 0.87 2.76 ± 0.83 2.80 ± 0.79 2.75 ± 0.86 0.35
Dyslipidemia, n (%) 264 (50.8) 184 (58.8) 0.025 171 (50.4) 93 (51.4) 77 (55.0) 107 (61.8) 0.088
albumin-adjusted-Calcium (mg/dL) 8.93 ± 0.35 9.09 ± 0.40 < 0.001 8.92 ± 0.36 8.96 ± 0.32 9.04 ± 0.41 9.13 ± 0.39 < 0.001
Phosphate (mg/dL) 3.54 ± 0.47 3.57 ± 0.44 0.420 3.52 ± 0.46 3.58 ± 0.48 3.58 ± 0.43 3.56 ± 0.45 0.503










Table 2 Characteristics of subjects categorized by albumin-adjusted serum calcium quartiles
Characteristics Albumin-adjusted calcium concentration (mg/dL) P
value8.42-8.69 8.70-8.93 8.94-9.22 9.23-10.42
n 213 237 181 202
Age (year) 67.9 ± 11.4 66.6 ± 13.3 68.3 ± 12.6 68.4 ± 12.9 0.188
Male, n (%) 142 (66.7) 143 (60.3) 99 (54.7) 102 (50.5) 0.006
Hypertension, n (%) 105 (49.3) 120 (50.6) 89 (49.2) 115 (56.9) 0.353
ACEI/ARB use, n (%) 101 (47.4) 98 (41.4) 76 (42.0) 103 (51.0) 0.150
Smoking, n (%) 57 (26.8) 54 (22.8) 37 (20.4) 42 (20.8) 0.402
Duration of diabetes (year) 10.1 ± 8.0 10.4 ± 9.1 10.7 ± 8.1 10.4 ± 8.7 0.041
SBP (mmHg) 137.1 ± 19.2 137.8 ± 19.6 135.4 ± 21.6 137.2 ± 18.3 0.672
DBP (mmHg) 79.2 ± 10.0 79.6 ± 11.2 79.5 ± 12.2 78.8 ± 10.8 0.894
BMI (kg/m2) 24.5 ± 3.4 24.5 ± 4.1 24.3 ± 4.0 24.0 ± 3.8 0.105
Obesity, n (%) 25 (11.7) 37 (15.6) 31 (17.1) 31 (15.3) 0.472
Laboratory
FPG (mmol/L) 7.04 ± 1.97 7.57 ± 2.82 7.88 ± 3.04 8.92 ± 4.16 < 0.001
lg HOMA-IR 0.53 ± 0.30 0.57 ± 0.32 0.61 ± 0.33 0.63 ± 0.36 0.011
HbA1c (%) 8.12 ± 1.96 7.94 ± 1.74 8.17 ± 1.95 8.34 ± 2.06 0.181
Albumin (g/L) 39.72 ± 4.42 38.90 ± 5.44 38.91 ± 4.16 36.85 ± 5.14 0.002
Uric acid (μmol/L) 320.68 ± 95.21 336.17 ± 97.88 336.90 ± 98.26 359.72 ± 113.81 0.913
Creatinine (μmol/L) 78.36 ± 20.31 83.13 ± 25.94 82.61 ± 24.86 85.24 ± 26.32 0.531
lg Alb/Cr (mg/g) 1.60 ± 0.71 1.65 ± 0.72 1.79 ± 0.68 1.83 ± 0.66 < 0.001
Micro-albuminuria, n (%) 107 (50.2) 126 (53.2) 113 (62.4) 130 (64.4) 0.007
TG (mmol/L) 1.79 ± 1.10 1.85 ± 1.17 1.73 ± 1.05 1.94 ± 1.39 0.329
TC (mmol/L) 4.59 ± 1.12 4.89 ± 1.07 4.77 ± 1.26 4.98 ± 1.19 0.003
HDL-C (mmol/L) 1.08 ± 0.31 1.12 ± 0.28 1.19 ± 0.56 1.06 ± 0.27 0.301
LDL-C (mmol/L) 2.63 ± 0.82 2.77 ± 0.79 2.62 ± 0.92 2.88 ± 0.85 0.004
Dyslipidemia, n (%) 114 (53.5) 123 (51.9) 87 (48.1) 124 (61.4) 0.060
albumin-adjusted-Calcium (mg/dL) 8.57 ± 0.08 8.84 ± 0.07 9.10 ± 0.08 9.52 ± 0.26 < 0.001
Phosphate (mg/dL) 3.48 ± 0.43 3.54 ± 0.44 3.61 ± 0.47 3.59 ± 0.49 0.021
LV dimension
LVIDD (mm) 47.56 ± 4.19 47.03 ± 4.82 47.22 ± 4.57 47.99 ± 4.42 0.142
LVIDS (mm) 29.89 ± 4.20 30.09 ± 3.62 30.49 ± 4.32 30.89 ± 4.46 0.066
IVSD (mm) 10.27 ± 1.45 10.84 ± 1.52 10.66 ± 1.59 11.13 ± 1.73 < 0.001
PWTD (mm) 9.48 ± 1.24 9.91 ± 1.34 9.93 ± 1.22 10.09 ± 1.45 < 0.001
RWT 0.40 ± 0.06 0.43 ± 0.08 0.42 ± 0.06 0.42 ± 0.07 < 0.001
LVMI (g/m2) 94.20 ± 19.02 101.51 ± 21.62 101.77 ± 22.65 111.21 ± 27.93 < 0.001
LVEF (%) 65.77 ± 7.45 64.68 ± 6.97 63.69 ± 8.26 64.87 ± 7.53 0.056
LV geometry
Normal (%) 54.0 40.9 35.4 31.2
< 0.001
Concentric remodeling (%) 23.0 21.5 27.6 15.3
Eccentric hypertrophy (%) 12.2 18.1 15.5 21.3
Concentric hypertrophy (%) 10.8 19.4 21.5 32.2
LVH, (%) 23.0 37.6 37.0 53.5 < 0.001
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Table 3 Correlation coefficients between albumin-adjusted
serum calcium and various parameters
Albumin-adjusted serum calcium
r P value
Age (year) 0.025 0.477
Duration of diabetes (year) −0.004 0.900
SBP (mmHg) 0.022 0.522
DBP (mmHg) −0.011 0.751
BMI (kg/m2) −0.006 0.862
FPG (mmol/L) 0.207 < 0.001
lg HOMA-IR 0.137 < 0.001
HbA1c (%) 0.040 0.254
Uric acid (μmol/L) 0.165 < 0.001
TG (mmol/L) 0.100 0.004
TC (mmol/L) 0.119 0.001
HDL-C (mmol/L) −0.043 0.212
LDL-C (mmol/L) 0.094 0.007
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3.713), p < 0.001]. Of note, this association between calcium
and LVH maintained significantly in model 1, model 2
and model 3, whether the albumin-adjusted serum cal-
cium was analyzed as a quartile-categorized variable or a
continuous variable.
To evaluate the predictive performance of albumin-
adjusted serum calcium for LVH, the AUC in ROC
curve was calculated. Alb/Cr and SBP which represent-
ing albuminuria and hypertension respectively and being
well-known risk factors for LVH were used as references
(Figure 1). The AUCs of albumin-adjusted serum calcium,
Alb/Cr and SBP were as follows: 0.617 [95% CI (0.577-
0.656), p < 0.001]; 0.668 [95% CI (0.630-0.705), p < 0.001];
0.597 [95% CI (0.558-0.636), p < 0.001]. Approximate to
Alb/Cr and SBP, albumin-adjusted serum calcium signifi-
cantly predicted LVH.
LV Geometry
From normal LV geometry to concentric remodeling, ec-





B Std. error β
lg Alb/Cr 7.430 1.145 0.219
Albumin- adjusted serum calcium 12.141 2.039 0.193
Creatinine 0.117 0.032 0.121
Obesity 5.130 2.109 0.077
Albumin −0.397 0.165 −0.083
Dyslipidemia 3.329 1.536 0.070
VIF: variance inflation factor.adjusted serum calcium levels significantly (p < 0.001) in-
creased from 8.92 ± 0.36 to 8.96 ± 0.32, 9.04 ± 0.41 and
9.13 ± 0.39 mg/dl, respectively (Table 1). Phosphate con-
centrations had no significant differences among groups
categorized by LV geometry.
Table 2 summarized echocardiographic parameters cate-
gorized by albumin-adjusted serum calcium quartiles.
IVSD, PWTD, RWT, and LVMI of subjects in quartile 4
(9.23-10.42 mg/dl) were significantly higher than those in
quartile 1 (8.42-8.69 mg/dl). As an important indicator of
systolic function, LVEF had a non-significant (p = 0.056)
overall downward tendency from quartile 1 to quartile 4,
but was significant different between quartile 1 and quar-
tile 3 (65.77 ± 7.45 vs. 63.69 ± 8.26%, p = 0.009). LVIDS
had a non-significant (p = 0.066) overall upward ten-
dency across albumin-adjusted serum calcium quartiles,
but was significant different between quartile 1 and quar-
tile 4 (29.89 ± 4.20 vs. 30.89 ± 4.46 mm, p = 0.019).
From albumin-adjusted serum calcium quartile 1 to quar-
tile 4, percentage of the subjects with normal LV geometry
decreased significantly from 54.0% to 31.2%; by contrast,
percentage of the subjects with LV eccentric hypertrophy
and concentric hypertrophy increased sharply from 12.2%
to 21.3%, 10.8% to 32.2%, respectively (Table 2).
Discussion
LVH is very common in T2DM [2-6]. Very recent studies
demonstrate that an increase in serum calcium concentra-
tions is associated with an increased risk of T2DM [11,12].
Hence an important question arises whether elevated serum
calcium contributes to LVH prevalence in T2DM.
To the best of our knowledge, this is the first analysis
of the association between changes in albumin-adjusted
serum calcium levels and the risk of LVH that focused
specifically on T2DM patients with normocalcemia and
normophosphatemia. Our results showed a clear association
between the elevated albumin-adjusted serum calcium levels
and the increased risk of LVH. Such an association is inde-
pendent of the effect of Alb/Cr, SBP, dyslipidemia, the use
of ACEI/ARB medication, age, gender, smoking, HbA1c,
obesity and HOMA-IR.ed t value p value 95.0% CI for B Collinearity
statistics
Tolerance VIF
6.486 < 0.001 5.182 - 9.678 0.877 1.140
5.953 < 0.001 8.138 - 16.143 0.948 1.055
3.609 < 0.001 0.053 - 0.180 0.889 1.124
2.433 0.015 0.991 - 9.269 0.994 1.007
−2.408 0.016 −0.721 - −0.073 0.836 1.196
2.168 0.030 0.315 - 6.343 0.955 1.047
Table 5 OR (95% CI) of LVH according to albumin-adjusted serum calcium concentration
Model Quartiles of albumin-adjusted serum calcium (mg/dL) Continuous variable
8.42-8.69 8.70-8.93 8.94-9.22 9.23-10.42
n 213 237 181 202 833
Crude model 1.000 (reference) 2.013 (1.331-3.043), 0.001 1.967 (1.268-3.052), 0.003 3.845 (2.521-5.865), < 0.001 3.063 (2.086-4.500), < 0.001
Model 1 1.000 (reference) 2.018 (1.313-3.102), 0.001 1.848 (1.171-2.915), 0.008 3.483 (2.237-5.425), < 0.001 2.727 (1.824-4.077), < 0.001
Model 2 1.000 (reference) 1.864 (1.182-2.942), 0.007 1.590 (0.979-2.582), 0.061 2.903 (1.806-4.665), < 0.001 2.449 (1.597-3.756), < 0.001
Model 3 1.000 (reference) 1.836 (1.152-2.924), 0.011 1.624 (0.992-2.658), 0.054 2.909 (1.792-4.720), < 0.001 2.400 (1.552-3.713), < 0.001
Values are OR (95% CI) and P value.
Model 1: adjusted for lg Alb/Cr, creatinine, albumin, and SBP.
Model 2: further adjusted for age, gender and smoking and the use of ACEI/ARB medication.
Model 3: further adjusted for Dyslipidemia, HbA1c, Obesity and lg HOMA-IR.
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levels of albumin-adjusted serum calcium (as well as calcium-
phosphate product), and higher but non-significant levels
of serum phosphate than those without LVH. On the
other hand, patients in the highest serum calcium quartile
had significantly higher percentage of LVH than those in
the lowest quartile. Previous studies have demonstrated a
high incidence of LVH both in patients with hypercalce-
mia (often hypophosphatemia) caused by primary hyper-
parathyroidism and in patients with hyperphosphatemia
(often hypocalcemia) caused by uremia and secondary
hyperparathyroidism [21-25]. Though parathyroid hor-
mone per se plays an important role, an acute impairment
in left ventricular diastolic function may be predominantly
due to elevated serum calcium level but not plasma para-
thyroid hormone [26,27]. Moreover, hyperphosphatemia
is an independent risk factor for LVH [23,28], and in-
creased calcium-phosphate product contributes to LVH
and left ventricular diastolic function impairment [23,24].Figure 1 ROC curves of the ability of albumin-adjusted serum calcium, AlbHowever, in subjects with normal ranges of serum calcium
and phosphate, the relationship between serum calcium/
phosphate and LVH is unknown. Our study indicates that
elevated serum calcium though in normal range is related
to LVH prevalence in T2DM.
LVH is an ominous predictor of cardiovascular outcomes
and is a multifactorial process with many causes. However,
it has often been ignored, to some extent, because of two
common misconceptions that LVH only occurs in severe
hypertension and ACEI/ARB can cure LVH [3]. Although
hypertension is regarded as a leading cause of LVH [1], evi-
dence demonstrates that blood pressure explains only 25%
of the variability in LV mass [29].
In the current study, the stepwise multiple linear regres-
sion analysis showed a significantly association between
albumin-adjusted serum calcium and LVMI. Moreover,
consistent with previous studies [1,30-34], renal insuffi-
ciency (characterized by higher Alb/Cr and creatinine as
well as lower serum albumin), obesity, and dyslipidemia/Cr and SBP to predict LVH.
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57.1% subjects (47.3% in non-LVH, 73.5% in LVH) in this
study had micro-albuminuria, it was unsurprising that
Alb/Cr had a highest standardized coefficient among all
independent variables in the stepwise multiple linear re-
gression. As a major LVH risk, elevated albumin-adjusted
serum calcium is second only to albuminuria (standard-
ized coefficients: 0.193 and 0.219, respectively). Albumin-
adjusted serum calcium, hypertension (indexed by SBP)
and albuminuria (indexed by Alb/Cr) had similar predict-
ive performance for LVH which evaluated by AUCs in
ROC curve (0.617, 0.597 and 0.668, respectively). In the
Insulin Resistance Atherosclerosis Study, individuals with
albumin-adjusted serum calcium level ≥ 9.5 mg/dl were at
significantly increased risk (OR = 1.79) of developing dia-
betes [12]. In our study, subjects with calcium level (9.23-
10.42 mg/dl) had a sharply increased risk (OR = 2.909) for
LVH than subjects with calcium level (8.42-8.69 mg/dl);
and for per 1 mg/dl increase in calcium level, the OR for
LVH was 2.400. These results suggested that moderate
changes of calcium level, even in the normal range, had
important clinical significance.
In this study, women had a higher prevalence of LVH
than men (57.1% vs. 23.7%, p < 0.001). This observed
gender differences could be partially accounted for by the
greater prevalence of micro-albuminuria (63.1% vs. 52.9%,
p = 0.003) and obesity (19.0% vs. 11.9%, p = 0.005), as well
as the poorer glucose control (HbA1c: 8.31 ± 1.90 vs. 8.00
± 1.93%, p = 0.021) in women. These results are consistent
with two previous large-scale hospital-based studies,
which showed that women with T2DM were less likely
than men to achieve therapeutic targets and diabetes con-
ferred a greater increase of cardiovascular risk in women
than in men [35,36]. Moreover, many studies supported a
more pronounced impact of diabetes (as well as other
metabolic syndrome factors) on left ventricular structure/
function in women than in men [37-40]. However, it is
interesting but unclear whether alterations in calcium
homeostasis, like metabolic disorders, have a sex-specific
effect on left ventricular hypertrophy. Thus, our future
study will explore in detail the interaction of these factors
on development of LVH.
As an essential characteristic of T2DM, insulin resistance
is accompanied with an increase in intracellular calcium
[41,42]. Ours and others [10,43] studies demonstrated a
positive correlation between insulin resistance (indexed by
HOMA-IR) and serum calcium level. In consistent with
this, serum calcium level is inversely associated with insulin
sensitivity measured with euglycaemic-hyperinsulinaemic
clamp in the normocalcemic general population [44]. How-
ever, it is controversial whether insulin resistance plays a
role in the pathogenesis of LVH, with some studies [45,46]
showing a clear relationship while others [5,47] having no
significant association between insulin resistance and LVH.In our study, there was an increased [OR (95% CI) = 1.486
(0.969-2.280)] but non-significant (p = 0.069) risk for LVH
in individuals with insulin resistance (logarithmically trans-
formed HOMA-IR as a continuous variable). Further stud-
ies are warranted to validate the association between
insulin resistance and LVH.
The calcium ion is an essential regulator for a great di-
versity of physiology processes, including contraction of
cardiac, skeletal, and smooth muscle; neurotransmitter
release; various forms of endocrine and exocrine secre-
tion; and automaticity of nerve and muscle [48]. We can
speculate about the mechanisms underlying the association
between serum calcium and LVH. On the one hand, the
alteration in serum calcium could act as a common link
among various metabolic disorders. In our study, albumin-
adjusted serum calcium level was significantly and posi-
tively correlated with metabolism-related parameters such
as FPG, HOMA-IR, uric acid, TG, TC and LDL-C. These
results are in line with previous studies that show a direct
association between albumin-adjusted serum calcium levels
and metabolism parameters of blood lipids and glucose
[8,10,43,49,50]. A health screening survey with over 18,000
adult participants showed that serum calcium concentra-
tion was positively related to serum glucose and cholesterol
concentrations [8]. In another study with 1,182 healthy sub-
jects, after adjusting for 25-OH vitamin D and parathyroid
hormone, significant positive correlations between glucose
and insulin resistance (indexed by HOMA-IR) with calcium
were found in both sexes, whereas an inverse correlation
between beta-cell function (indexed by HOMA-β) and cal-
cium was found only in women [43]. Conversely, only in
men, serum calcium level was positively associated with im-
paired glucose metabolism (indexed by fasting blood glu-
cose) in a cross-sectional study with 480 T2DM patients;
and this association was independent of PTH or bone me-
tabolism [10]. In the national prevention program of dia-
betes in Finland with 2896 participants, serum calcium
level is even associated with metabolic syndrome and its
components except HDL-C, after adjustment for age, phys-
ical activity, alcohol, vitamin D intake, calcium intake, and
smoking [49]. Given that various metabolic abnormalities,
such as diabetes, central obesity, dyslipidemia and hyperuri-
cemia have been reported in association with LVH, even in
the absence of hypertension [1,3,32,51,52], these results
suggest that increased serum calcium level may correlate
with LVH through metabolic abnormalities. On the other
hand, left ventricular function is sensitive to disorders in
calcium metabolism [27]. The contraction and relaxation of
both vascular smooth muscle cells and cardiomyocytes are
highly dependent on cytosolic calcium homeostasis [26,28].
Calcium has a hypertrophic action on heart cells [21]. A
positive calcium balance can accelerate soft-tissue and vas-
cular calcification which may potentially lead to impaired
left ventricular relaxation even without hypercalcemia
Li et al. Cardiovascular Diabetology  (2015) 14:43 Page 9 of 11[28,53]. Calcium increase is a potential trigger of the
translocation of pro-hypertrophic transcription factors
which involved in the cardiac development to the nucleus
[54]. Sustained elevation in intracellular calcium may lead
to excessive activation of calcineurin pathway in the heart,
and cardiomyocytes from calcineurin transgenic hearts are
disorganized and markedly hypertrophic [55,56]. Calcium
homeostasis impairment also is a prominent feature in the
transition from compensatory hypertrophy to heart failure
[54]. In additional, hemodynamics can be altered by varia-
tions in serum calcium through changes in left ventricular
stroke volume and output [28]; and essential hypertension
can alter calcium metabolism which in turn provokes the
development of myocardial hypertrophy [57].
Our study chose a selected population (T2DM patients
with normal serum calcium, phosphate and creatinine,
without macro-albuminuria). Without overt biochemical
abnormalities or symptoms in these patients, alterations
in calcium homeostasis are easy to be ignored in our clin-
ical practice. These findings suggest that in T2DM pa-
tients equal attention should be paid to increased serum
calcium and traditional risk factors for LVH such as albu-
minuria and hypertension.
Several limitations of this study must be taken into ac-
count when interpreting the results. First, in our study no
measurements of serum levels of parathyroid hormone and
Vitamin D are available for most of the population, so it is
impossible to absolutely exclude confounding factors such
as primary hyperparathyroidism and secondary hyperpara-
thyroidism due to vitamin D deficiency. A previous study
found 30 cases (0.6%) with normal serum calcium and in-
appropriately high serum PTH (normocalcemic primary
hyperparathyroidism) in 5202 subjects, using the diagnos-
tic criteria including serum calcium 2.50-2.60 mmol/l with
PTH ≥ 35 ng/L and calcium < 2.50 mmol/l with PTH >
55 ng/L [58]. However, even without associated distur-
bances in serum PTH, serum calcium per se in the refer-
ence range is positively associated with cardiovascular
endpoints such as myocardial infarction [59,60]. Since
serum calcium levels are well-known lower or low-normal
in individuals with secondary hyperparathyroidism caused
by vitamin D deficiency and/or renal insufficiency, in our
study, secondary hyperparathyroidism (as well as corre-
sponding vitamin D deficiency and/or renal insufficiency)
cannot account for the higher rate of LVH among patients
in the higher serum calcium quartiles. Because the levels
of serum calcium as well as phosphate are regulated in a
coordinated way and there are important interactions be-
tween calcium and phosphate [61], to minimize the possi-
bility that some abnormal conditions may influence the
results, we excluded individuals with serum calcium and
phosphate levels outside the normal range. Second, ion-
ized calcium which is the physiologically active form [62],
was not measured in our study. However, total serumcalcium level (adjusted with serum albumin to which cal-
cium is bound) is highly correlated with ionized calcium
level, and is still widely used in current clinical practice. In
several recent studies [10-12], albumin-adjusted total cal-
cium is used for assess the association between serum cal-
cium level and risk of T2DM. Third, the subjects in this
study were Chinese, and our findings may not be relevant
to other ethnic populations. Finally, the sample size in our
study is moderate; the hospital-based study is susceptible
to sample selection bias; and cause-effect relationship can-
not be drawn from the cross-sectional study.
Conclusions
In summary, our results extend previous identified associ-
ation of calcium homeostasis with LVH from hyperparathyr-
oidism with dyscalcemia to T2DM with normocalcemia.
The increased albumin-adjusted serum calcium level, even
within the physiological ranges, is independently associ-
ated with LVH prevalence in patients with T2DM.
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